Comparative characterization and cytotoxicity study of TAT-peptide as potential vectors for siRNA and Dicer-substrate siRNA

References

• Crombez L, Divita G. A non-covalent peptide-based strategy for siRNA delivery. Methods Mol Biol 2011;683:349–60
   PubMedGoogle Scholar
• Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009;61:850–62
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Z, Wientjes MG, Au JLS. Delivery of siRNA therapeutics: barriers and carriers. AAPS J 2010;12:492–503
   PubMed Web of Science ®Google Scholar
• Amarzguioui M, Rossi JJ. Principles of dicer substrate (D-siRNA) design and function. Methods Mol Biol 2008;442:3–10
   PubMedGoogle Scholar
• Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005;23:222–6
   PubMed Web of Science ®Google Scholar
• Te P, Sarret P, Dore L, Beaudet N. Application of Dicer-substrate siRNA in pain research. Pain 2010:161–90 . doi: 10.1007/978-3-642-12168-5_7
   Google Scholar
• Kubo T, Zhelev Z, Ohba H, Bakalova R. Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity. Oligonucleotides 2007;17:445–64
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim NY, Choi YB, et al. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release 2010;143:335–43
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Nishikawa M, Takakura Y. Nonviral vector-mediated RNA interference: Its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev 2009;61:760–6
   PubMed Web of Science ®Google Scholar
• Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2:711–19
   PubMed Web of Science ®Google Scholar
• Malhotra M, Kulamarva A, Sebak S, et al. Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Dev Ind Pharm 2009;35:719–26
   PubMed Web of Science ®Google Scholar
• Manosroi J, Lohcharoenkal W, Gotz F, et al. Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide. Drug Dev Ind Pharm 2013;39:520–5
   PubMed Web of Science ®Google Scholar
• Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36:4158–71
   PubMed Web of Science ®Google Scholar
• Brooks H, Lebleu B, Vivès E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 2005;57:559–77
   PubMed Web of Science ®Google Scholar
• Meade BR, Dowdy SF. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev 2008;60:530–6
   PubMed Web of Science ®Google Scholar
• Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010–17
   PubMed Web of Science ®Google Scholar
• Holzerny P, Ajdini B, Heusermann W, et al. Biophysical properties of chitosan/siRNA polyplexes: profiling the polymer/siRNA interactions and bioactivity. J Control Release 2012;157:297–304
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008;60:548–58
   PubMed Web of Science ®Google Scholar
• Kleemann E, Neu M, Jekel N, et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Control Release 2005;109:299–316
   PubMed Web of Science ®Google Scholar
• Yi WJ, Yang J, Li C, et al. Enhanced nuclear import and transfection efficiency of Tat peptide-based gene delivery systems modified by additional nuclear localization signals. Bioconjugate Chem 2012;23:125–34
   PubMed Web of Science ®Google Scholar
• Scholz C, Wagner E. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J Control Release 2012;161:554–65
   PubMed Web of Science ®Google Scholar
• Law M, Jafari M, Chen P. Physicochemical characterization of siRNA-peptide complexes. Biotechnol Progr 2008;24:957–63
   PubMed Web of Science ®Google Scholar
• Mullerv RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3–19
   PubMed Web of Science ®Google Scholar
• Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006;14:476–84
   PubMed Web of Science ®Google Scholar
• Malhotra M, Tomaro-duchesneau C, Prakash S. Biomaterials synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 2012;34:1270–80
   PubMed Web of Science ®Google Scholar
• Hickerson RP, Vlassov AV, Wang Q, et al. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 2008;18:345–54
   PubMed Web of Science ®Google Scholar
• Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 2006;115:216–25
   PubMed Web of Science ®Google Scholar
• Liu HA, Liu YL, Ma ZZ, et al. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model. Invest Ophth Vis Sci 2011;52:4789–94
   PubMed Web of Science ®Google Scholar